We therefore assessed the incidence of Clostridioides difficile infection (CDI), Clostridium innocuum (CI) infection, and cytomegalovirus (CMV) colitis in IBD patients treated with Vedolizumab (VDZ), anti-tumor necrosis factor agents (anti-TNF), or Ustekinumab (UST).<h4>Methods</h4>This single‐center, retrospective cohort study included IBD patients who initiated VDZ, anti‐TNF (infliximab or adalimumab) or UST at Chang Gung IBD Center between January 2017 and December 2024. This evidence concerns the gene TNF and clostridium difficile infection.